Role of fibrinogen, albumin and fibrinogen to albumin ratio in determining angiographic severity and outcomes in acute coronary syndrome

• DOI: 10.4330/wjc.v15.i1.13
• Publication Date: 2023-01-11T14:09:28Z
• Authors: Kunaal Makkar; Yash Paul Sharma; Akash Batta; Juniali Hatwal; Prashant Kumar Panda
• Keywords: TIMI; Culprit

Coronavirus disease 2019 (COVID-19) pandemic unmasked the huge deficit in healthcare resources worldwide. It highlighted need for efficient risk stratification management of cardiovascular emergencies.To study applicability old, available and affordable nonconventional biomarkers: albumin fibrinogen their ability to predict angiographic severity clinical outcomes patients with acute coronary syndrome (ACS).In this prospective, observational study, 166 consecutive ACS were enrolled. Fibrinogen, ratio determined from serum. Patients underlying chronic liver disease, active malignancy, autoimmune COVID-19 infection undergoing thrombolysis excluded.Mean age population was 60.5 ± 1.5 years, 74.1% being males. ST elevation myocardial infarction (STEMI) most common presentation seen 57% patients. Fibrinogen (FAR) ≥ 19.2, had a sensitivity 76.9% specificity 78.9 % [area under receiver operating characteristic curves (AUROC) = 0.8, P 0.001] ≤ (TIMI) 1 flow culprit artery STEMI Even non-STEMI patients, FAR 18.85 predicted same 80% 63% (AUROC 0.715, 0.006).Novel biomarkers, high cost, lack availability long turn over time are impractical real-world use. Identifying TIMI has significant impact outcome. Our shown that readily biomarkers like can help identify these high-risk good accuracy. This allows risk-stratification individualization treatment ACS.